Bovidec for the active immunisation of breeding cattle-Hyperdrug

Bovidec for the active immunisation of adult female breeding cattle, by vaccination prior to service/insemination as an aid in the prevention of infection with BVD Type I virus during the first trimester of pregnancy. It is during this period that such infections can lead to persistent infection of the foetus with BVDV, a pre-requisite for Mucosal Disease (MD) in later life. Results from studies available to date indicate that the protection afforded against BVD Type I should exist for at least 420 days post-initial vaccination. It has also been shown under field conditions that the vaccine may reduce the incidence of herd infertility when a diagnosis of infertility is associated with clinical manifestations of BVD infection. Calves For the active immunisation of calves as an aid in the prevention of viraemia and to reduce viral shredding of BVD Type I virus once maternal antibodies have declined. The duration of immunity is 13 months. For the active immunisation of calves to reduce viraemia and the clinical signs of BVD Type II virus, once maternal antibody levels have declined. Results from studies available to date indicate that the reduction in symptoms afforded should exist for at least 21 days following the vaccination course.

Significant changes New claim against Type II BVDV in calves - Presentation Bovidec is a pink, aqueous suspension containing an inactivated non-cytopathogenic strain of Bovine Viral Diarrhoea Virus (BVDV). The vaccine is adjuvanted with Quil-A (1 mg/dose) and preserved with thiomersal at a concentration of 0.013% w/v. Uses Adult Breeding Cattle For the active immunisation of female breeding cattle, by vaccination prior to service/insemination as an aid in the prevention of infection with BVD Type I virus during the first trimester of pregnancy. It is during this period that such infections can lead to persistent infection of the foetus with BVDV, a pre-requisite for Mucosal Disease (MD) in later life. Results from studies available to date indicate that the protection afforded against BVD Type I should exist for at least 420 days post-initial vaccination. It has also been shown under field conditions that the vaccine may reduce the incidence of herd infertility when a diagnosis of infertility is associated with clinical manifestations of BVD infection. Calves For the active immunisation of calves as an aid in the prevention of viraemia and to reduce viral shredding of BVD Type I virus once maternal antibodies have declined. The duration of immunity is 13 months. For the active immunisation of calves to reduce viraemia and the clinical signs of BVD Type II virus, once maternal antibody levels have declined. Results from studies available to date indicate that the reduction in symptoms afforded should exist for at least 21 days following the vaccination course.

Dosage and administration Dose 4 ml. Administration By subcutaneous injection. Shake the container well before withdrawing the dose. It is recommended that vaccination be made high on the side of the neck. The primary vaccination course comprises 2 doses of vaccine separated by a 3 week interval. Primary vaccination Adult Breeding Cattle The vaccination programme should completed not less than 7 days prior to service, to ensure full efficacy of the vaccine. Calves Calves can be vaccinated from 3.5 months of age if maternal antibody has declined. Where calves are likely to be seropositive the minimum age of primary vaccination should be 5 months. Booster vaccination When used as an aid in the prevention of BVD infection during the first trimester of pregnancy and in calves: Study has shown that administration of a single 4ml dose 14 months after the primary vaccination is sufficient to boost the serological response to BVDV Type I. A single annual booster is recommended. Reduction in the incidence of herd infertility: Study has shown that administration of a single 4ml dose 14 months after the primary vaccination is sufficient to boost the serological response to BVDV Type I. A single 4ml dose should be administered not less than 7 days prior to service.

Contra-indications, warnings, etc For animal treatment only. Occasional hypersensitivity reactions may occur as with all vaccines. Should anaphylaxis occur use epinephrine (adrenaline). Do not administer to animals that have previously shown a hypersensitivity reaction. Transient pyrexia and injection site inflammatory reactions may occur. The pyrexia is unassociated with any other clinical illness, the animals continuing to behave and eat normally. The local reaction consists of a diffuse, subcutaneous oedema which subsides over 2–3 weeks. In any group of animals, a small number of individuals may fail to respond to vaccination as a result of immunological incompetence or for some other reason. Satisfactory immune responses will only be attained in healthy animals. Thus it is important to avoid vaccination of animals which have intercurrent disease, are on a course of concomitant therapy or have poor nutritional status. Bovidec can be administered to pregnant cattle. Administration of Bovidec during one or other of the trimester periods has demonstrated no difference in the overall outcome of pregnancy, compared with unvaccinated control animals. When pregnant animals are vaccinated it should be remembered that the calves they are carrying may have already been exposed to virus if the dam was naďve in the earlier stages of pregnancy. Syringes and needles should be sterile and the injection made through an area of clean, dry skin taking precautions against contamination. Withdrawal period Zero days. Pharmaceutical precautions Keep out of reach of children. Store at between +2° and +8°C. Do not freeze. Shake the container well before withdrawing the dose. Broached containers should be used immediately. No information is available regarding the possible interaction of Bovidec with other vaccines administered concomitantly. Therefore it is recommended that no other vaccines are administered within 14 days before or after vaccination with Bovidec.

Legal category POM-V (previously POM). Packaging Quantities 20 ml glass vial. 200 ml glass vial. Further information Antibody to the BVDV strain used in Bovidec has been shown to cross neutralise a broad panel of BVDV isolates. Due to the nature of the disease it is recommended that all breeding females on a given farm are included in a vaccination programme. Marketing authorisation number Vm 18343/4004.